{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:09:22Z","timestamp":1791590962446,"version":"4.3.4"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":1185,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The Osteosarcoma Surveillance Study was initiated in the United States in 2003 to monitor for a potential association between the osteoporosis treatment teriparatide and osteosarcoma. Osteosarcoma occurs at a background incidence rate of approximately 2.5 cases per million per year in US adults aged 40\u2009years or older. For this study, incident cases of osteosarcoma diagnosed between January 1, 2003, and December 31, 2016, were identified through participating cancer registries in the United States. Information on prior exposure to medications and possible risk factors was obtained by self-report (or proxy report) in telephone interviews. Exposure information was verified through medical record abstraction for a sample of patients. A standardized incidence ratio was estimated to compare the observed and expected numbers of osteosarcoma patients with a prior history of teriparatide treatment. Interviews were completed for 24% (1173) of patients diagnosed with osteosarcoma between 2003 and 2016; three reports of teriparatide use before diagnosis were identified. Based on the background incidence rate, the expected number of osteosarcoma cases among patients treated with teriparatide was 4.17. Given the three observed cases, the standardized incidence ratio was 0.72 (90% confidence interval [CI], 0.20 to 1.86). Demographic characteristics were similar for interviewed and noninterviewed patients. Agreement was &amp;gt;90% between self-reported and chart-recorded exposure to osteoporosis medications. Mean age of interviewed patients was 61\u2009years; 53% of patients were male, 84% were white, and 5% were Hispanic. The prevalence of suspected risk factors for development of osteosarcoma among the osteosarcoma cohort was 19% for history of radiation and 4% for history of Paget's disease of bone. These findings showed that the incidence of osteosarcoma associated with teriparatide use during the 15-year surveillance period was no different than would be expected based on the background incidence rate of osteosarcoma. \u00a9 2020 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).<\/jats:p>","DOI":"10.1002\/jbmr.4188","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T17:19:50Z","timestamp":1601399990000},"page":"244-251","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9266-1417","authenticated-orcid":false,"given":"Alicia","family":"Gilsenan","sequence":"first","affiliation":[{"name":"RTI Health Solutions Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk","family":"Midkiff","sequence":"additional","affiliation":[{"name":"RTI Health Solutions Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Harris","sequence":"additional","affiliation":[{"name":"RTI Health Solutions Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Kellier-Steele","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McSorley","sequence":"additional","affiliation":[{"name":"RTI Health Solutions Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth B","family":"Andrews","sequence":"additional","affiliation":[{"name":"RTI Health Solutions Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"issue":"3","key":"2024012713525180500_jbmr4188-bib-0001","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2\u2009years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"issue":"4","key":"2024012713525180500_jbmr4188-bib-0002","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","article-title":"Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose","volume":"32","author":"Vahle","year":"2004","journal-title":"Toxicol Pathol"},{"issue":"12","key":"2024012713525180500_jbmr4188-bib-0003","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1359\/jbmr.080807","article-title":"Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]","volume":"23","author":"Vahle","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2024012713525180500_jbmr4188-bib-0004","author":"Eli Lilly and Company","year":"2002"},{"key":"2024012713525180500_jbmr4188-bib-0005","author":"Gilsenan","year":"2019"},{"key":"2024012713525180500_jbmr4188-bib-0006","volume-title":"Pathology and genetics: tumours of soft tissue and bone","author":"Fletcher","year":"2002"},{"key":"2024012713525180500_jbmr4188-bib-0007","volume-title":"Dahlin's bone tumor: general aspects and data on 11,087 cases","author":"Unni","year":"1996","edition":"5th ed"},{"issue":"2","key":"2024012713525180500_jbmr4188-bib-0008","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0959-8049(02)00478-1","article-title":"Osteosarcoma over the age of forty","volume":"39","author":"Grimer","year":"2003","journal-title":"Eur J Cancer"},{"issue":"1","key":"2024012713525180500_jbmr4188-bib-0009","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ijc.24320","article-title":"International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons","volume":"125","author":"Mirabello","year":"2009","journal-title":"Int J Cancer"},{"issue":"7","key":"2024012713525180500_jbmr4188-bib-0010","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/cncr.24121","article-title":"Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results program","volume":"115","author":"Mirabello","year":"2009","journal-title":"Cancer"},{"key":"2024012713525180500_jbmr4188-bib-0011","doi-asserted-by":"crossref","first-page":"548151","DOI":"10.1155\/2011\/548151","article-title":"Using epidemiology and genomics to understand osteosarcoma etiology","volume":"2011","author":"Savage","year":"2011","journal-title":"Sarcoma"},{"key":"2024012713525180500_jbmr4188-bib-0012","author":"National Cancer Institute (NCI)","year":"2013"},{"issue":"Suppl 334","key":"2024012713525180500_jbmr4188-bib-0013","first-page":"67","article-title":"European postmarketing adult osteosarcoma surveillance study: characteristics of patients: a preliminary report","volume":"80","author":"von Sch\u00e9ele","year":"2009","journal-title":"Acta Orthop"},{"issue":"10","key":"2024012713525180500_jbmr4188-bib-0014","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1007\/s00198-018-4604-8","article-title":"The Forteo patient registry linkage to multiple state cancer registries: study design and results from the first 8\u2009years","volume":"29","author":"Gilsenan","year":"2018","journal-title":"Osteoporos Int"},{"issue":"12","key":"2024012713525180500_jbmr4188-bib-0015","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/jbmr.1768","article-title":"The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7\u2009years","volume":"27","author":"Andrews","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2024012713525180500_jbmr4188-bib-0016","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/pds.4008","article-title":"The experience of accommodating privacy restrictions during implementation of a large-scale surveillance study of an osteoporosis medication","volume":"25","author":"Midkiff","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2024012713525180500_jbmr4188-bib-0017","author":"Midkiff","year":"2014"},{"key":"2024012713525180500_jbmr4188-bib-0018","author":"Kellier-Steele","year":"2017"},{"key":"2024012713525180500_jbmr4188-bib-0019","author":"US Census Bureau","year":"2017"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.4188","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.4188","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/2\/244\/55458456\/jbmr4188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/2\/244\/55458456\/jbmr4188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T11:06:10Z","timestamp":1710327970000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/36\/2\/244-251\/7516739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,10,29]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.4188","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,10,29]]},"assertion":[{"value":"2020-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}